Analysis of thyroid carcinomas with immunohistochemical panel application: retrospectively study of 52 cases

Анализ карциномы щитовидной железы с применением иммуногистохимического метода: ретроспективное исследование 52 случаев
Mecdi Gurhan Balci 1, Mahir Tayfur 1 *
More Detail
1 Department of Pathology, Medical Faculty, Erzincan Binali Yıldırım University, Erzincan, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 3, Issue 53, pp. 32-37.
OPEN ACCESS 2800 Views 1537 Downloads
Download Full Text (PDF)


Aim: The aim of this study was to share our cases of thyroid carcinoma with the literature and to emphasize the importance of evaluation with an immunohistochemical panel in cases with difficulty in the differential diagnosis.
Background: Thyroid carcinomas are the most common malignant endocrine tumors. Its incidence is 1% among all cancer. They constitute 0.2% of cancer-related deaths. The papillary carcinoma is the most common group with 70-90%. It has the best prognosis. It is diagnosed by the presence of nuclear features such as the appearance of clarification in the core, the inclusion body, and the core like a groove. Follicular carcinoma is the second most common thyroid tumor with 10-15%. In the differential diagnosis of follicular carcinoma, the capsular invasion and vascular invasion are important. Medullary carcinoma constitutes 3-5% of all thyroid carcinomas. Immunohistochemical stains such as calcitonin, CEA, CK7, chromogranin, synaptophysin, and Congo-Red were applied to confirm the diagnosis of medullary carcinoma. Anaplastic thyroid carcinoma constitutes 1-2% of all thyroid carcinomas. Cellular pleomorphism in the anaplastic carcinoma is higher than that of other thyroid carcinomas.
Results: In this retrospective study, of the 52 thyroid carcinoma cases, 45 (86.6%) were papillary carcinoma, 4 (7.7%) were follicular carcinoma, 2 (3.8%) were anaplastic carcinoma, and 1 (1.9%) was medullary carcinoma.
Conclusion: In the diagnosis of thyroid pathologies, mainly cellular properties are determinative. The evaluation with the immunohistochemical panel will reduce the risk of diagnostic error when the cases that difficultly diagnosed with cellular properties.


Balci MG, Tayfur M. Analysis of thyroid carcinomas with immunohistochemical panel application: retrospectively study of 52 cases. Journal of Clinical Medicine of Kazakhstan. 2019;3(53):32-7.


  • Sadullahoğlu C, Sayıner A, Süren D, Yıldırım HT, Nergiz D, Sezer C, Oruç MT. The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions. Indian J Pathol Microbiol. 2019; 62(2):206-210.
  • LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011; 24(2):1-9.
  • Pellegriti G, Frasca F, Regalbuto C, Squadrito S, Vigneri R. World wide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212.
  • Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein T. Epidemiology of thyroid cancer: a review of the national cancer database, 2000-2013. Cureus. 2019; 11(2):e4127.
  • Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am. 2012; 96(2):329-349.
  • Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall survival of papillary thyroid carcinoma patients: A single-institution long-term follow-up of 5897 patients. World J Surg. 2018; 42(3):615-622.
  • Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, et al. The impact of age and gender on a papillary thyroid cancer survivor. J Clin Endocrinol Metab. 2012; 97(6):878-887.
  • Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, et al. The influence of patientage on thyroid nodule formation, multinodularity, and thyroid cancer risk. J Clin Endocrinol Metab. 2015; 100(12):4434-4440.
  • Clark KJ, Cronan JJ, Scola FH. Color Doppler sonography: anatomic and physiologic assessment of the thyroid. J Clin Ultrasound. 1995; 23:215-223.
  • Yeung MJ, Serpell JW. Management of the solitary thyroid nodule. The Oncologist. 2008; 13(2):105-112.
  • Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK. Anaplastic thyroid carcinoma: An overview. Curr Oncol Rep. 2007; 9:152-158.
  • Shin HJ, Hwang KA, Choi KC. Antitumor effect of various phytochemicals on diverse types of thyroid cancers. Nutrients. 2019; 11(1).
  • Marques P, Leite V, Bugalho MJ. Retrospective analysis of 255 papillary thyroid carcinomas ≤2 cm: clinicohistological features and prognostic factors. Eur Thyroid J. 2014; 3(4):258-263.
  • Kwak JY, Kim EK, Kim JK, et al. Dual primingoligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. HeadNeck. 2010; 32:490-498.
  • Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016; 375(11):1054-1067.
  • Nikiforov YE, Ohori NP. Papillary carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR editors. Diagnostic pathology and molecular genetics of the thyroid: A comprehensive guide for practicing thyroid pathology. 2nd edition. Philadelphia: WolterKluver /Lippincott Williams &Wilkins; 2012; 183-246.
  • Boerner SL, Asa SL. Biopsy interpretation series: Biopsy interpretation of the thyroid. Epstein JI, editor. Philadelphia: WolterKluver /Lippincott Williams &Wilkins; 2009; 267.
  • Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008; 132(3):359-372.[359:AOITTN]2.0.CO;2
  • Parameswaran R, Shulin Hu JS, En NM, Tan WB, Yuan NK. Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann R Coll Surg Engl. 2017; 99(2):151-154.
  • Zidan J, Kassem S, Kuten A. Follicular carcinoma of the thyroid gland: prognostic factors, treatment, and survival. Am J Clin Oncol. 2000; 23(1):1-5.
  • Sobrinho-Simoes M, Asa SL, Kroll TG, Nikiforov Y, DeLeillis R, Farid P, et al. In: World Health Organization classification of tumors: pathology and genetics of tumors of endocrine organs. DeLeillis RA, Lloyd RV, Heitz PU, Eng C, editor. Lyon: IARC Press; Follicular Carcinoma. 2004; 67-72.
  • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
  • Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. The American thyroid association guidelines task force on medullary thyroid carcinoma. Thyroid. 2015; 25(6): 567-610.
  • Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-upstudy. J Clin Endocrinol Metab. 2008; 93:682-687.
  • Machens A, Dralle H. Simultaneous medullary and papillary thyroid cancer: a novel entity? Ann Surg Oncol. 2012; 19:37-44.
  • Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017; 13(11):644-660.
  • Rivera M, Sang C, Gerhard R, Ghossein R, Lin O. Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. Acta Cytol. 2010; 54(5):668-672.
  • Gietka-Czernel M. The thyroid gland in postmenopausal women: physiology and diseases. Prz Menopauzalny. 2017; 16(2):33-37.
  • Sidibé el H. Thyroid diseases in sub-Saharan Africa. Sante. 2007; 17(1):33-39.
  • Do Cao C, Wémeau JL. Current management of thyroid malignancies. Presse Med. 2009; 38(2):210-219.
  • Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. J Clin Endocrinol Metab. 2018; 103(2):689-697.
  • Robertson B, Parker M, Shepherd L, Panieri E, Cairncross L, Malherbe F, et al. Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma. Cancers Head Neck. 2018; 3:10.